188813-07-2Relevant articles and documents
On-Nanoparticle Gating Units Render an Ordinary Catalyst Substrate- And Site-Selective
Kim, Minju,Dygas, Miroslaw,Sobolev, Yaroslav I.,Beker, Wiktor,Zhuang, Qiang,Klucznik, Tomasz,Ahumada, Guillermo,Ahumada, Juan Carlos,Grzybowski, Bartosz A.
supporting information, p. 1807 - 1815 (2021/02/05)
When an organometallic catalyst is tethered onto a nanoparticle and is embedded in a monolayer of longer ligands terminated in "gating"end-groups, these groups can control the access and orientation of the incoming substrates. In this way, a nonspecific catalyst can become enzyme-like: it can select only certain substrates from substrate mixtures and, quite remarkably, can also preorganize these substrates such that only some of their otherwise equivalent sites react. For a simple, copper-based click reaction catalyst and for gating ligands terminated in charged groups, both substrate- and site-selectivities are on the order of 100, which is all the more notable given the relative simplicity of the on-particle monolayers compared to the intricacy of enzymes' active sites. The strategy of self-assembling macromolecular, on-nanoparticle environments to enhance selectivities of "ordinary"catalysts presented here is extendable to other types of catalysts and gating based on electrostatics, hydrophobicity, and chirality, or the combinations of these effects. Rational design of such systems should be guided by theoretical models we also describe.
BIS AROMATIC COMPOUNDS FOR USE AS LTC4 SYNTHASE INHIBITORS
-
Page/Page column 71, (2010/10/03)
There is provided compounds of formula (I), wherein Y, ring A1 D1, D2a, D2b, D3, L1, Y1, L3 and Y3 have meanings given in the description, and pharmaceutica
META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS
-
, (2008/06/13)
The present invention relates to a class of compounds represented by the Formula Ior a pharmaceutically acceptable salt thereof, whereinA ispharmaceutical compositions thereof and methods of using such compounds and compositions as alphavbeta3 antagonists.
